Dr. Tabbara on the Expansion of Treatment Options for AML

Video

In Partnership With:

Imad Tabbara, MD, discusses the expansion of treatment options for patients with acute myeloid leukemia.

Imad Tabbara, MD, professor of medicine, director of the Blood & Bone Marrow Transplant Program, and Fellowship Training Program, GW Cancer Center, discusses the expansion of treatment options for patients with acute myeloid leukemia (AML).

Ten years ago, treatment for AML was limited to 7+3 induction chemotherapy which consists of 7 days of cytarabine followed by 3 days of an anthracycline, which is usually daunorubicin, says Tabbara.

Now, it is understood that AML is a heterogeneous disease that requires options to treat the individual needs of patients, Tabbara explains.

Today, many treatment options are available including targeted therapies forpatients with FLT3-mutated, CD33-positive, and IDH1/2-mutated disease. Although these mutations were not unknown, Tabbara says, targeted therapy development was lacking.

Tabbara is confident the options will only expand further as the field continues to grow.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD